Retatrutide (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Once weekly sub-Q on the trial cohort obese ladder shown above. The six day half-life means a new dose does not reach steady plasma levels for about 3 weeks, so a heart rate or nausea response to one step can surface only after the next step has already been taken; holding each dose at least 4 weeks is the single rule that prevents most trouble. Speed matters more than destination: the Phase 2 arm that jumped in 4 mg steps carried sustained GI symptoms across all 48 weeks, while every slower arm faded to single digit rates by month nine. Bridge rungs are not optional either, so 5 mg and 6 mg belong in the ladder before 8 mg or 9 mg. At 4 mg and above, splitting the weekly dose every 3 days is worth considering, since GI and heart rate effects track peak concentration after an injection rather than the weekly total; the same cumulative exposure at a lower peak improves tolerability without changing efficacy. At this concentration a 12 mg week is 1.20 mL, which is split across two injection sites regardless.

Results Timeline

Sequence described in the research record. Individual response varies.

• Weeks 1 to 20: stepwise titration, 4 weeks per rung, with GI symptoms concentrated during the climb.
• Week 24: about 75% of eventual weight loss is already banked and appetite suppression has reached most of its long run effect.
• Week 24: resting heart rate peaks, 6 to 9 bpm above baseline at 12 mg in the trial cohort.
• Week 48: heart rate eases to about 5 bpm as weight loss rebalances autonomic tone, while liver fat reduction is still moving.
• After the last dose: appetite returns over about 30 days and glucagon driven metabolic rate defense fades within weeks, so a reasoned 8 to 12 week step down at 2 to 4 mg is used as maintenance runway.

Reconstitution Steps

1. Draw 1.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe.
5. Ladder conversions at 10 mg/mL: 0.3 mg = 3 units; 0.5 mg = 5 units; 1 mg = 10 units; 2 mg = 20 units; 4 mg = 40 units; 8 mg = 80 units; 9 mg = 90 units; 12 mg = 120 units, which exceeds one U-100 syringe and splits into two injections.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C (-4 °F) in dry, dark conditions; stable for 12 months or longer.
• Reconstituted: refrigerate at 2 to 8 °C (35.6 to 46.4 °F) and avoid freeze thaw cycles.

• Allow vials to reach room temperature before opening, which reduces condensation uptake.
• Keep reconstituted vials out of the refrigerator door, where temperature swings are largest, and label each one with date and concentration so draw volumes are never guessed.

Supplies Needed

Planning math is based on a 24 week titration from 0.5 mg up to 8 mg weekly maintenance on the trial cohort obese ladder.

Peptide Vials (Retatrutide, 10 mg vial):

• That 24 week course totals about 104 mg, which is about 11 vials at 10 mg each; extending to 48 weeks and a 12 mg top dose totals about 290 mg, or about 30 vials. Ongoing 8 mg weekly maintenance runs 32 mg per month, about 4 vials; 1 mg microdose maintenance runs 4 mg per month, about one vial every 2.5 months.

Insulin Syringes (U-100):

• Per week: 1 U-100 syringe at doses through 8 mg, 2 at 12 mg because the volume exceeds one syringe, and up to 3 when a weekly dose of 8 to 12 mg is split every 3 days.
• Full cycle: 24 syringes across 24 weeks at one injection weekly, or 48 across 48 weeks; double either figure when high doses are split.

Bacteriostatic Water (10 mL bottles):

• Each 10 mg vial takes 1.0 mL, so one 10 mL bottle covers 10 vials: 2 bottles for the 24 week course and about 5 bottles for a year of 8 mg weekly maintenance.

Alcohol Swabs:

• Per injection: 2 swabs, one for the vial stopper and one for the skin.
• Full cycle: about 48 swabs over 24 weeks at one injection weekly, and about 104 for a year of weekly maintenance, which one 100 count box covers.

Important Notes

Practical considerations for consistency and safety.

• Lean phenotype ladder (BMI 22 to 28): start 0.3 mg (3 units), effective band 2 to 4 mg (20 to 40 units). Heart rate, not nausea, is the dominant concern here, because a healthy cardiovascular system reads the same glucagon signal far harder and there is no large weight loss to bring the rate back down. Resting heart rate is tracked weekly through any increase, with an ECG check at each step at 6 mg and above. This phenotype sits outside the published trial population, so the dosing logic comes from receptor pharmacology and Phase 1 single dose data, not chronic lean trials.
• T2D obese ladder (BMI 30 to 40): start 0.5 mg (5 units), effective band 4 to 9 mg (40 to 90 units). The HbA1c lever is loud in this group and the heart rate signal is comparatively quiet; the evidence basis is the Phase 2 T2D trial.
• Microdose ladder, any phenotype: start 0.3 mg (3 units) and sit in a 0.5 to 1 mg band (5 to 10 units). This is GIP forward with light appetite effect and no meaningful heart rate cost, aimed at the liver fat and visceral fat signal that the 1 mg arm measured directly. A lighter body sees 20 to 40% more drug per kg than the trial cohort at the same milligrams.
• Titration discipline: hold each dose at least 4 weeks, never skip bridge rungs, and split the weekly dose at 4 mg and above if tolerability is the limiting factor. When switching from tirzepatide, the maximum tirzepatide dose is not carried straight across; tirzepatide builds tolerance at GIP and GLP-1 receptors but none at glucagon, so 1 to 2 mg is the restart point.
• Baseline panel before the first dose: resting heart rate as a weekly average, fasting glucose and HbA1c, lipid panel, thyroid panel including free T3, and liver enzymes. Free T3 matters because the glucagon arm suppresses active thyroid hormone while a TSH only panel can still read normal, so unexplained fatigue or cold intolerance at upper doses warrants a free T3 check. Contraindications named in the source material: personal or family history of medullary thyroid carcinoma, MEN2 syndrome, pre existing atrial fibrillation, known structural heart disease, pregnancy or breastfeeding, and severe gastroparesis.
• Regulatory Note: retatrutide is not FDA approved and remains investigational, with the Phase 3 TRIUMPH program running through 2026 to 2027. Vials are research grade, not pharmaceutical grade. Absence of approval is not a verdict on efficacy, since the Phase 2 obesity results were among the strongest ever published. WADA status is not addressed in the source material.

How This Works

Native GIP, GLP-1, and glucagon are gut and pancreatic hormones that fire for a few minutes after a meal and then clear. Retatrutide is a weekly injection with a six day half-life that holds all three receptors engaged around the clock for months, turning brief natural pulses into steady continuous pressure, and each receptor does a different job. The GIP receptor governs how fat cells handle energy through SERCA mediated futile calcium cycling and dampens nausea through a brainstem GABAergic brake circuit; retatrutide binds it roughly an order of magnitude tighter than tirzepatide, so most of that engagement is already in place by 1 to 4 mg and higher doses add little. The GLP-1 receptor drives appetite suppression at hypothalamic and brainstem sites, slows gastric emptying, and sets tolerability through the area postrema nausea pathway; it is still climbing across the entire range and is only about 52% engaged at 12 mg, which is why appetite suppression and nausea both keep rising. The glucagon receptor tells the liver to oxidize its own stored fat, defends resting energy expenditure against the post weight loss drop, and carries most of the dose scaling heart rate rise; it scales last and reaches continuous engagement above the natural range only at the upper doses. The ladder therefore shifts which receptor does the marginal work: at 1 mg it is mostly GIP with light GLP-1, and at 12 mg the GIP receptor is saturated while added dose buys appetite pressure plus the glucagon liver and heart signal. The brainstem brake circuit that buffers nausea has to fire alongside a low GLP-1 signal long enough to wire in, a plasticity window, which is why fast escalation hits the nausea pathway before the brake is built and produces sustained GI symptoms across the whole dosing period.

Benefits & Side Effects

Observations from the published record.

• Weight loss anchors: Phase 2 obesity (Jastreboff 2023) reported 24.2% mean weight loss at 12 mg over 48 weeks in participants with obesity and without diabetes (BMI 37, about 110 kg), with the 1 mg arm at 8.7%. The Phase 3 TRIUMPH-4 readout reported 28.7% at 12 mg over 68 weeks in obesity with osteoarthritis.
• Dose response shape: half of the maximum effect arrives by about 4 mg and 8 mg captures roughly 94% of the 12 mg effect, so returns compress past 8 mg. About 75% of eventual loss lands by week 24, while liver fat reduction is still moving at week 48.
• Liver, lipid, kidney, and glycemic signal: in the MASLD substudy, liver fat fell 51% at 1 mg and 86% at 12 mg over 48 weeks, with steatosis resolved in 93% at the top dose. Triglycerides fell about 60% and LDL about 25% through glucagon driven ANGPTL3/8 suppression, UACR fell 31%, and HbA1c fell 1.39% at 4 mg over 36 weeks in T2D. The liver effect is substrate gated: a lean user without liver fat shows the biochemical signal as ketones rise but no scan visible reduction.
• Heart rate cost: a GLP-1 floor of 2 to 4 bpm plus a glucagon contribution that scales with dose, peaking at 6 to 9 bpm at 12 mg around week 24 in the trial cohort and easing to about 5 bpm by week 48 as weight loss rebalances autonomic tone. Lean users land harder and do not get that post weight loss compensation, so the peak is closer to a chronic reality.
• Side effects: nausea, vomiting, diarrhea, and slowed digestion from the GLP-1 arm, scaling with dose and peaking during titration; dysesthesia, meaning burning or tingling skin sensitivity, at upper doses from the glucagon arm; free T3 suppression alongside a normal TSH, also from the glucagon arm; injection site reactions. Stopping creates stronger regain pressure than semaglutide or tirzepatide, since appetite returns over about 30 days while hunger hormone signals stay elevated for up to a year after major weight loss.
• Covariates and composition: women lost about 4.2 kg more than men at the same dose, the largest sex difference of any compound studied, and effect declines about 3% per year above age 50. Across the class about 25% of total weight lost is fat free mass and roughly half of that is skeletal muscle, with slow titration producing more visceral fat reduction and fast titration pulling more lean mass. Hair loss, mood effects, and specific cognitive symptoms were not pre specified in the trial adverse event inventory, so published data is genuinely silent rather than reassuring.

Lifestyle Factors

Complementary strategies for best outcomes.

• Protein at 1.6 g/kg of body weight per day or more. Across the class about 25% of weight lost is fat free mass, and protein adequacy is the primary lever that reduces it during an aggressive deficit.
• Resistance training 3 to 4 times weekly, the second primary lever for lean mass preservation, since strength loss tracks faster than weight loss without it.
• Hydration, electrolytes, and fiber, with slow protein anchored meals kept small and frequent during titration, because gastric slowing drops meal volume tolerance sharply and dehydration amplifies nausea. Alcohol is limited during active titration, since ethanol amplifies the nausea pathway and works against lean mass preservation.
• Weekly tracking of resting heart rate through any dose increase, with a smartwatch ECG check at each step at 6 mg and above and a hold rather than a step if resting heart rate is still climbing at week 16 of a dose. Sleep and energy are tracked weekly too, since unexplained fatigue at upper doses is the trigger for a free T3 check. Some protocols add L-Carnitine for fatigue management during a deficit and MOTS-c for mitochondrial capacity under rapid fat mobilization.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and injection site with alcohol; allow to dry completely.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. For volumes above 1.0 mL, split into 2 injections at different sites (e.g., left and right abdomen).
5. Rotate sites systematically (abdomen preferred; also thighs, upper arms) to avoid lipohypertrophy.
6. Wait a few seconds after injecting before withdrawing needle to ensure full dose delivery.
7. Dispose of used syringes immediately in an FDA-approved sharps container.

References

Source citations for further reading.

1. Jastreboff AM et al. Triple hormone receptor agonist retatrutide for obesity, Phase 2 trial (NEJM, 2023).
2. Rosenstock J et al. Retatrutide for type 2 diabetes, Phase 2 (Lancet, 2023).
3. Sanyal AJ et al. Retatrutide MASLD substudy: 86% liver fat reduction (Nat Med, 2024).
4. Coskun T et al. Retatrutide receptor pharmacology, GIP receptor potency vs tirzepatide (Cell Metab, 2022).
5. Eli Lilly TRIUMPH-4 Phase 3 readout: 28.7% at 12 mg over 68 weeks in obesity with osteoarthritis (Dec 2025).
6. Goodman et al. Cardiac chronotropy mechanism, glucagon arm dose scaling (Br J Clin Pharmacol, 2025).